Trial intelligence / Profile preview

Phase 2 Study of Dasatinib vs Dasatinib plus BMS-833923 in Newly Diagnosed Chronic Phase Ph+ CML

2011-000083-10Phase 2Completed

Sponsor

Bristol Myers Squibb

Start

Jul 2011

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1